KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 74 filers reported holding KARYOPHARM THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 0.49 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,138,154 | -70.1% | 1,311,536 | -48.0% | 0.00% | – |
Q1 2024 | $3,805,805 | +84.7% | 2,520,105 | +5.8% | 0.00% | – |
Q4 2023 | $2,061,034 | -32.8% | 2,382,428 | +4.2% | 0.00% | – |
Q3 2023 | $3,065,176 | -19.9% | 2,287,146 | +7.0% | 0.00% | – |
Q2 2023 | $3,825,398 | -44.5% | 2,137,094 | +20.6% | 0.00% | -100.0% |
Q1 2023 | $6,892,041 | +147102.9% | 1,771,733 | +28.7% | 0.00% | 0.0% |
Q4 2022 | $4,682 | -99.9% | 1,377,128 | +3.5% | 0.00% | 0.0% |
Q3 2022 | $7,264,000 | +21.5% | 1,330,435 | +0.3% | 0.00% | 0.0% |
Q2 2022 | $5,981,000 | -39.3% | 1,326,319 | -0.9% | 0.00% | 0.0% |
Q1 2022 | $9,860,000 | +6.3% | 1,337,888 | -7.3% | 0.00% | 0.0% |
Q4 2021 | $9,276,000 | +13.3% | 1,442,731 | +2.5% | 0.00% | 0.0% |
Q3 2021 | $8,189,000 | -33.6% | 1,407,157 | +17.7% | 0.00% | -50.0% |
Q2 2021 | $12,335,000 | +2.3% | 1,195,278 | +4.2% | 0.00% | 0.0% |
Q1 2021 | $12,063,000 | -25.1% | 1,146,715 | +10.3% | 0.00% | -33.3% |
Q4 2020 | $16,096,000 | +4.5% | 1,039,847 | -1.5% | 0.00% | 0.0% |
Q3 2020 | $15,407,000 | -21.2% | 1,055,335 | +2.2% | 0.00% | -25.0% |
Q2 2020 | $19,557,000 | +9.1% | 1,032,592 | +10.6% | 0.00% | -20.0% |
Q1 2020 | $17,928,000 | -43.5% | 933,327 | -43.6% | 0.01% | +66.7% |
Q4 2019 | $31,706,000 | +318.3% | 1,653,944 | +109.9% | 0.00% | +50.0% |
Q3 2019 | $7,579,000 | +64.0% | 787,879 | +2.1% | 0.00% | +100.0% |
Q2 2019 | $4,622,000 | +34.9% | 771,703 | +31.5% | 0.00% | 0.0% |
Q1 2019 | $3,426,000 | -67.2% | 586,659 | -47.4% | 0.00% | -50.0% |
Q4 2018 | $10,454,000 | +15.5% | 1,115,854 | +109.9% | 0.00% | -33.3% |
Q3 2018 | $9,052,000 | +3.3% | 531,569 | +3.1% | 0.00% | 0.0% |
Q2 2018 | $8,759,000 | +103.1% | 515,596 | +60.5% | 0.00% | +200.0% |
Q1 2018 | $4,312,000 | +60.1% | 321,323 | +14.5% | 0.00% | 0.0% |
Q4 2017 | $2,693,000 | -7.5% | 280,610 | +5.8% | 0.00% | 0.0% |
Q3 2017 | $2,911,000 | +23.6% | 265,121 | +1.8% | 0.00% | 0.0% |
Q2 2017 | $2,356,000 | +8.7% | 260,419 | +54.3% | 0.00% | 0.0% |
Q1 2017 | $2,167,000 | +47.3% | 168,770 | +7.8% | 0.00% | 0.0% |
Q4 2016 | $1,471,000 | +3.2% | 156,493 | +6.8% | 0.00% | 0.0% |
Q3 2016 | $1,425,000 | +48.1% | 146,487 | +2.1% | 0.00% | 0.0% |
Q2 2016 | $962,000 | -22.2% | 143,471 | +3.4% | 0.00% | 0.0% |
Q1 2016 | $1,237,000 | -32.6% | 138,717 | +0.1% | 0.00% | 0.0% |
Q4 2015 | $1,836,000 | +28.0% | 138,644 | +1.7% | 0.00% | 0.0% |
Q3 2015 | $1,434,000 | -60.1% | 136,269 | +3.2% | 0.00% | -50.0% |
Q2 2015 | $3,592,000 | -4.7% | 132,030 | +7.2% | 0.00% | 0.0% |
Q1 2015 | $3,768,000 | +30.2% | 123,113 | +59.2% | 0.00% | 0.0% |
Q4 2014 | $2,893,000 | +6.6% | 77,314 | -0.4% | 0.00% | 0.0% |
Q3 2014 | $2,713,000 | +20.9% | 77,658 | +61.0% | 0.00% | +100.0% |
Q2 2014 | $2,244,000 | +62.8% | 48,220 | +8.1% | 0.00% | 0.0% |
Q1 2014 | $1,378,000 | +69.7% | 44,621 | +25.9% | 0.00% | 0.0% |
Q4 2013 | $812,000 | – | 35,455 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Consonance Capital Management LP | 4,827,078 | $82,205,000 | 4.43% |
Palo Alto Investors LP | 4,663,324 | $79,416,000 | 3.21% |
Private Capital Advisors, Inc. | 473,901 | $8,071,000 | 2.23% |
DOHENY ASSET MANAGEMENT /CA | 215,445 | $3,669,000 | 1.92% |
Sandia Holdings, LLC | 119,739 | $2,039,000 | 0.96% |
Capital Impact Advisors, LLC | 102,006 | $1,744,000 | 0.60% |
Birchview Capital, LP | 50,000 | $852,000 | 0.55% |
EMERALD ADVISERS, LLC | 694,068 | $11,820,000 | 0.43% |
EMERALD MUTUAL FUND ADVISERS TRUST | 647,307 | $11,024,000 | 0.37% |
Schonfeld Strategic Advisors LLC | 418,100 | $7,121,000 | 0.32% |